Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 15/20 | 0.56 |
| ▸ | PPARA | Q07869 | 15/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16825731 | 1.00 | KDM6B (0.56) | KDM6BPPARGPPARASLC6A4SLC6A2 | |
| SCHEMBL2459377 | 1.00 | KDM6B (0.56) | KDM6BPPARGPPARASLC6A4SLC6A2 | |
| SCHEMBL10891346 | 0.89 | KDM6B (0.67) | KDM6B | |
| SCHEMBL6712771 | 0.83 | PPARG (0.59) | PPARGPPARASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL9658999 | 0.82 | SLC6A4 (0.47) | PPARGPPARASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL19369765 | 0.82 | SLC6A2 (0.48) | KDM6BPPARGPPARASLC6A4SLC6A2 | |
| SCHEMBL1901447 | 0.82 | SLC6A4 (0.52) | PPARGPPARASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4663230 | 0.81 | CYP1A2 (0.65) | PPARGPPARASLC6A4 | |
| SCHEMBL235131 | 0.81 | KDM6B (0.63) | KDM6BSLC6A2 | |
| SCHEMBL289562 | 0.81 | KDM6B (0.63) | KDM6BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883720-B2 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | POLYPHOR AG (CH) | 2014-11-11 | — | — | US | disclosed |
| US-20110312879-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2011-12-22 | — | — | US | disclosed |
| WO-2010060479-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2010-06-03 | — | — | WO | disclosed |
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1417190-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgen Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | KDM6B 2996/4885PPARG 47/4885PPARA 112/4885 |
| US-20110312879-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | CXCL12, CXCR4, CXCR1 | KDM6B 4503/4885PPARG 1778/4885PPARA 2168/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | KDM6B 2996/4885PPARG 47/4885PPARA 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.